Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
William HintonAbdus Samad AnsariMartin Brunel WhyteAndrew P McGovernMichael D FeherNeil MunroSimon de LusignanPublished in: Diabetes, obesity & metabolism (2022)
Real-world SGLT2 inhibitor use supports randomized trial data for the size effect of reduced hospitalization for heart failure in type 2 diabetes, although with a much lower ARR in people without CVD.